| 2025 | 2024 | 2023 | 2022 | |||||
|---|---|---|---|---|---|---|---|---|
| Gross margin | -3,9 k € | -156.5% | 7,0 k € | -25.8% | 9,4 k € | -32.2% | 13,9 k € | |
| EBITDA | -4,7 k € | -178.5% | 6,0 k € | -20.3% | 7,6 k € | -42.9% | 13,3 k € | |
| Operating profit | -6,3 k € | -228.4% | 4,9 k € | -21.3% | 6,2 k € | -39.5% | 10,3 k € | |
| Profit/loss | -6,5 k € | -387.1% | 2,3 k € | -34.6% | 3,5 k € | -53.6% | 7,5 k € | |
| Equity | 8,7 k € | -42.8% | 15,3 k € | +17.5% | 13,0 k € | +36.6% | 9,5 k € | |
| Total assets | 32,8 k € | +10.7% | 29,6 k € | +19.1% | 24,9 k € | +32.6% | 18,7 k € | |
| Cash | 6,0 k € | -19.3% | 7,4 k € | -31.2% | 10,8 k € | +138.2% | 4,5 k € | |
| Debts | 24,0 k € | +67.9% | 14,3 k € | +20.8% | 11,9 k € | +28.4% | 9,2 k € | |
Source: Belgian Official Gazette
Private limited company · Gembloux · incorporated on 14/04/2022
Private limited company loss-making in the latest fiscal year. Cash position declining (-19.3%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Perfusion Extracorporeal Technology is a Private limited company incorporated in 2022. Its main activity is: Other business support service activities n.e.c.. Its registered office is in Gembloux.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.